Open an account

Grifols SA

GRFS · BOLSA

$7.56+$0.11 (+1.48%)TodayMarket closed ·
Prev close $7.45

About GRFS

Grifols SA is a global specialty plasma therapeutics company that engages in the development, manufacturing, and distribution of a broad range of biological medicines based on plasma-derived proteins. The company is headquartered in Sant Cugat Del Valles, Barcelona and currently employs 25,258 full-time employees. The company went IPO on 2006-05-17. The firm organizes its business into five divisions: Bioscience, Diagnostic, Hospital, Bio Supplies and Others. Bioscience includes manufacturing activities of plasma derivatives for therapeutic use and the sale and distribution of end products. Its diagnostic focuses on researching, developing, manufacturing and marketing in vitro diagnostics products, such as analytical instruments, reagents and software, among others, for laboratories. Hospital offers technology and services for hospitals, clinics and specialized centers for the manufacture of medicines, as well as physiological saline solution, enteral nutritional fluids and medical devices for interventional therapy. Its bio Supplies provides, mostly, biological products for non-therapeutic use.

Employees
25,000
Headquarters
Sant Cugat del Valles, Barcelona
Listed
May 17, 2006
Sector
Health Care
Industry
Biotechnology
Website
grifols.com

GRFS key statistics

Market cap
5.98B
Price-earnings ratio
0.00
Dividend yield
2.14%
Average volume
537.17K
Volume
992.35K
Open price
$7.50
High today
$7.57
Low today
$7.49
52 Week high
$9.90
52 Week low
$6.96

Grifols SA (GRFS) at a glance

As of Oct 23, 2026, Grifols SA (GRFS) shares are priced at $7.56, giving the company a market cap of 5.98B, a price-to-earnings ratio of 0.00 and a dividend yield of 2.14%.

Today the stock has traded between $7.49 and $7.57. The current price is 0.9% above the day's low and 0.1% below its high.

Volume so far is 992.35K shares, above the average of 537.17K shares a day.

Over the past year Grifols SA has ranged from $6.96 to $9.90, and now sits 20% of the way up that range.

Grifols SA met or beat analyst EPS estimates in 3 of the last 6 quarters. In Q2 FY26 it reported $0.33 per share against an estimate of $0.1313.

The average analyst price target is $11.48, 51.9% above the current price, from 1 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

0%of 1 analyst rating say Buy
  • Buy0.0%
  • Hold100.0%
  • Sell0.0%
Price target · 19 analystsAvg $11.48
Low
$6.76
Now
$7.56
High
$17.96

GRFS earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 3 of the last 6 quarters, by 80.4% on average.

  1. Q2 FY22: reported $0.29 per share against an estimate of $0.3182
  2. Q4 FY22: reported $0.05 per share against an estimate of $0.2828
  3. Q2 FY23: reported $0.17 per share against an estimate of $0.4141
  4. Q2 FY25: reported $0.29 per share against an estimate of $0.1616
  5. Q4 FY25: reported $0.223 per share against an estimate of $0.202
  6. Q2 FY26: reported $0.33 per share against an estimate of $0.1313

GRFS news

  • Grifols Q1 Revenue €1.7 Billion Down From €1.786 Billion YoY

  • 'Grifols' Canadian License Restricted After Plasma Donor Deaths' - Bloomberg

  • Grifols Expects Reaching Free Cash Flow Pre-M&A Pre-Dividends Of €500M-575M; 2027 Milestones Unchanged; 2026 Adjusted EBITDA Margin Of Over 25%

  • Avi Kapoor

    Verona Pharma, Rhythm Pharmaceuticals, AES And Other Big Stocks Moving Higher On Wednesday

  • Press releaseBusiness Wire

    Mason Capital Management to Support Grifols Recommended Director Slate at Upcoming Ordinary General Meeting

  • Grifols Chairman Thomas Glanzmann To Retire; To Be Succeeded Ann-Catherine Berner

  • Press releaseBusiness Wire

    Mason Capital Management Sends Letter to Spanish National Securities Market Commission Regarding Lack of Transparency by Grifols

  • Press releaseBusiness Wire

    Mason Capital Management Requests Immediate Disclosure of Important Information Regarding Conflicted Grifols Director Tomas Daga

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.